

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

Provisional Stakeholder List


Consultees	Commentators (no right to submit or
	appeal)
Company	General
GlaxoSmithKline (belantamab	All Wales Therapeutics and Toxicology
mafodotin)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
African Caribbean Leukaemia Trust	Wales
Anthony Nolan	British National Formulary
Black Health Agency for Equality	Care Quality Commission
Blood Cancer UK	Department of Health, Social Services
Cancer Black Care	and Public Safety for Northern Ireland
Cancer Equality	Healthcare Improvement Scotland
Cancer52	Medicines and Healthcare products
DKMS	Regulatory Agency
Helen Rollason Cancer Charity	National Association of Primary Care
Independent Cancer Patients Voice	National Pharmacy Association
Kevin Karawa Leukaemia Trust	NHS Confederation
Leukaemia Cancer Society	Scottish Medicines Consortium
Leukaemia Care	Welsh Government
Macmillan Cancer Support	Welsh Health Specialised Services
Maggie's Centres	Committee
Marie Curie	
Myeloma UK	Possible comparator companies
South Asian Health Foundation	AbbVie (dexamethasone)
Specialised Healthcare Alliance	ADVANZ Pharma (dexamethasone,
Tenovus Cancer Care	lenalidomide)
	Amarox (lenalidomide) Amarox (confilmential)
Healthcare professional groups	Amgen (carfilzomib) AS Kalaska (dayamathasana)
Association of Cancer Physicians	AS Kalceks (dexamethasone)
British Blood Transfusion Society	Aspen (dexamethasone) Aspire Pharms (hortozomik
British Committee for Standards in	 Aspire Pharma (bortezomib, dexamethasone)
Haematology	•
British Geriatrics Society	Aurobindo Pharma (bortezomib)Bausch & Lomb UK (dexamethasone)
British Institute of Radiology	D: DI III/ (I'I 'I)
British Oncology Pharmacy	,
Association	Bristol Myers Squibb Pharmaceuticals

Provisional stakeholder list for evaluation of belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 Issue date: March 2024



Consultees Commentators (no right to submit or appeal) (lenalidomide, pomalidomide) British Psychosocial Oncology Society Dr. Reddy's Laboratories UK British Society for Haematology (bortezomib) **British Society of Interventional** Glenmark Pharmaceuticals Europe Radiology **British Transplantation Society** (dexamethasone, lenalidomide) Hameln pharma (dexamethasone) Cancer Research UK Hospira UK (dexamethasone) NHS Blood and Transplant Janssen-Cilag (bortezomib, Royal College of General Practitioners daratumumab) Royal College of Nursing Krka UK (dexamethasone) Royal College of Pathologists Royal College of Physicians Martindale Pharma, an Ethypharm Group Company (dexamethasone) Royal College of Radiologists Medac GmbH (bortezomib) Royal Pharmaceutical Society Menarini Stemline UK (selinexor) Royal Society of Medicine MSN Laboratories Europe (bortezomib) Society and College of Radiographers Mylan (bortezomib, lenalidomide) **UK Clinical Pharmacy Association** Novartis Pharmaceuticals UK UK Myeloma Society (dexamethasone) UK Oncology Nursing Society Panpharma UK (dexamethasone) ParaPharm Development Others (dexamethasone) Department of Health and Social Care • Pfizer (bortezomib, elranatamab) NHS England • Piramal Critical Care (lenalidomide) Ranbaxy UK Limited a Sun Pharmaceutical Company (bortezomib, lenalidomide) Rayner Pharmaceuticals (dexamethasone) Rosemont Pharmaceuticals (dexamethasone) Sandoz (bortezomib, lenalidomide) Sanofi (dexamethasone, isatuximab) • Santen UK (dexamethasone) • Synchrony Pharma (dexamethasone) Takeda UK (ixazomib) Teva UK (dexamethasone, lenalidomide) Thame Laboratories (dexamethasone) Thea Pharmaceuticals (dexamethasone) Thornton & Ross (bortezomib, lenalidomide) Tillomed Laboratories (bortezomib) Wockhardt UK (dexamethasone)

Provisional stakeholder list for evaluation of belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
	Zentiva (lenalidomide)ZR Pharma & GmBH (panobinostat)
	 Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK MRC Clinical Trials Unit National Institute for Health Research
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies Provisional stakeholder list for evaluation of belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 Issue date: March 2024





that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.